Kliniske studier for Gliom i Illinois
13 studier for Gliom søker deltakere på steder i Illinois.
Byer i Illinois
Offisiell studietekst (engelsk)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- University of Chicago Comprehensive Cancer Center, Chicago
- OSF Children's Hospital of Illinois, Peoria
RekruttererFase 1/2
12 Months – 21 Years · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05099003Targeted Pediatric High-Grade Glioma Therapy
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererObservasjonsstudie
12 Months – 39 Years · Alle kjønn · Oppdatert 8. sep. 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
Alder 12 til 39 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Chicago, Chicago
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. aug. 2026 · NCT05303519PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
Alder 3 til 39 · Alle kjønn · Oppdatert 24. aug. 2026 · NCT05096481Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 1
Alder 1 til 25 · Alle kjønn · Oppdatert 18. aug. 2026 · NCT04485559Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Chicago
RekruttererFase 1/2
Alder 18 til 130 · Alle kjønn · Oppdatert 12. aug. 2026 · NCT05417594A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
- Northwestern Medicine, Chicago
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT07464925MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 1/2
Alder 1 til 26 · Alle kjønn · Oppdatert 10. jul. 2026 · NCT06712875Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererTidlig fase 1Frivillige helsepersonell ønskes velkommen
Alder 1 til 21 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
12 Months – 39 Years · Alle kjønn · Oppdatert 29. mai 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Northwestern Memorial Hospital, Chicago
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. apr. 2026 · NCT06810544rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 1
12 Months – 18 Years · Alle kjønn · Oppdatert 17. mar. 2026 · NCT04943848Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.